These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 28167571)

  • 1. Pharmacoepidemiology of Clinically Relevant Hypothyroidism and Hypertension from Sunitinib and Sorafenib.
    Walko CM; Aubert RE; La-Beck NM; Clore G; Herrera V; Kourlas H; Epstein RS; McLeod HL
    Oncologist; 2017 Feb; 22(2):208-212. PubMed ID: 28167571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of thyroid hormone therapy in patients treated with sunitinib or sorafenib: a cohort study.
    Feldt S; Schüssel K; Quinzler R; Franzmann A; Czeche S; Ludwig WD; Schulz M
    Eur J Cancer; 2012 May; 48(7):974-81. PubMed ID: 22382202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thyroid dysfunction in patients treated with sunitinib or sorafenib.
    Clemons J; Gao D; Naam M; Breaker K; Garfield D; Flaig TW
    Clin Genitourin Cancer; 2012 Dec; 10(4):225-31. PubMed ID: 23017335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypothyroidism Side Effect in Patients Treated with Sunitinib or Sorafenib: Clinical and Structural Analyses.
    Shu M; Zai X; Zhang B; Wang R; Lin Z
    PLoS One; 2016; 11(1):e0147048. PubMed ID: 26784451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential use of sorafenib and sunitinib in advanced renal cell carcinoma: does the order of sequencing matter?
    Calvani N; Morelli F; Leo S; Orlando L; Lombardi L; Gnoni A; Cinefra M; Maiello E; Lorusso V; Cinieri S
    Med Oncol; 2012 Sep; 29(3):1908-13. PubMed ID: 21858552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
    Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
    Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
    [No Abstract]   [Full Text] [Related]  

  • 7. Thyroid size change by CT monitoring after sorafenib or sunitinib treatment in patients with renal cell carcinoma: comparison with thyroid function.
    Kitajima K; Takahashi S; Maeda T; Yoshikawa T; Ohno Y; Fujii M; Miyake H; Fujisawa M; Sugimura K
    Eur J Radiol; 2012 Sep; 81(9):2060-5. PubMed ID: 21724350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular toxicity after antiangiogenic therapy in persons older than 65 years with advanced renal cell carcinoma.
    Jang S; Zheng C; Tsai HT; Fu AZ; Barac A; Atkins MB; Freedman AN; Minasian L; Potosky AL
    Cancer; 2016 Jan; 122(1):124-30. PubMed ID: 26439451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy.
    Torino F; Corsello SM; Longo R; Barnabei A; Gasparini G
    Nat Rev Clin Oncol; 2009 Apr; 6(4):219-28. PubMed ID: 19333228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
    Zhao J; Zhu Y; Zhang C; Wang X; He H; Wang H; Wu Y; Zhou W; Shen Z
    Urol Oncol; 2013 Nov; 31(8):1800-5. PubMed ID: 22658883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis.
    Sheng X; Chi Z; Cui C; Si L; Li S; Tang B; Mao L; Lian B; Wang X; Yan X; Guo J
    Oncotarget; 2016 May; 7(19):27044-54. PubMed ID: 26894858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of efficacy, safety, and quality of life between sorafenib and sunitinib as first-line therapy for Chinese patients with metastatic renal cell carcinoma.
    Cai W; Kong W; Dong B; Zhang J; Chen Y; Xue W; Huang Y; Zhou L; Huang J
    Chin J Cancer; 2017 Aug; 36(1):64. PubMed ID: 28789709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis.
    Funakoshi T; Latif A; Galsky MD
    J Hum Hypertens; 2013 Oct; 27(10):601-11. PubMed ID: 23636006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypothyroidism in patients with renal cell carcinoma: blessing or curse?
    Schmidinger M; Vogl UM; Bojic M; Lamm W; Heinzl H; Haitel A; Clodi M; Kramer G; Zielinski CC
    Cancer; 2011 Feb; 117(3):534-44. PubMed ID: 20845482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
    La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
    Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypothyroidism during treatment with tyrosine kinase inhibitors.
    Zygulska AL; Krzemieniecki K; Sowa-Staszczak A
    Endokrynol Pol; 2012; 63(4):302-6. PubMed ID: 22933166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma.
    Park SJ; Lee JL; Park I; Park K; Ahn Y; Ahn JH; Lee DH; Ahn S; Song C; Hong JH; Kim CS; Ahn H
    Chemotherapy; 2012; 58(6):468-74. PubMed ID: 23548259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer.
    Eichelberg C; Vervenne WL; De Santis M; Fischer von Weikersthal L; Goebell PJ; Lerchenmüller C; Zimmermann U; Bos MM; Freier W; Schirrmacher-Memmel S; Staehler M; Pahernik S; Los M; Schenck M; Flörcken A; van Arkel C; Hauswald K; Indorf M; Gottstein D; Michel MS
    Eur Urol; 2015 Nov; 68(5):837-47. PubMed ID: 25952317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trials.
    Santoni M; Conti A; De Giorgi U; Iacovelli R; Pantano F; Burattini L; Muzzonigro G; Berardi R; Santini D; Cascinu S
    Int J Cancer; 2014 Aug; 135(4):763-73. PubMed ID: 24127298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Symptoms from treatment with sunitinib or sorafenib: a multicenter explorative cohort study to explore the influence of patient-reported outcomes on therapy decisions.
    Koldenhof JJ; Witteveen PO; de Vos R; Walraven M; Tillier CN; Verheul HM; Teunissen SC
    Support Care Cancer; 2014 Sep; 22(9):2371-80. PubMed ID: 24687539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.